<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2302">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04724434</url>
  </required_header>
  <id_info>
    <org_study_id>20-1020</org_study_id>
    <nct_id>NCT04724434</nct_id>
  </id_info>
  <brief_title>Follow-up Study of COVID-19 Patients in the District Konstanz</brief_title>
  <acronym>FSC19-KN</acronym>
  <official_title>Single Center Prospective Controlled Follow-up Study of COVID-19 Patients in the District Konstanz (FSC19-KN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hegau-Bodensee-Klinikum Singen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Hegau-Bodensee-Klinikum Singen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective single-center study for the follow-up of SARS-CoV-2 positive patients&#xD;
      in the district of Konstanz (LKN). As part of the coronavirus pandemic, patients with&#xD;
      SARS-CoV-2 infection are currently being treated in the clinics of the LKN's health network&#xD;
      at the Singen (Hegau-Bodensee Clinic) and Konstanz (Konstanz Clinic) locations. So far, there&#xD;
      is little data on the long-term effects of SARS-CoV-2 infection. As part of this study, the&#xD;
      disease progression of these patients will be monitored. Study objective: Prospective,&#xD;
      controlled follow-up observation of SARS-CoV-2 positive patients regarding their secondary&#xD;
      diseases and quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 4, 2020</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Hospitalization</measure>
    <time_frame>Between 1 year after enrollment and 5 years after last patient in</time_frame>
    <description>Primary endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L</measure>
    <time_frame>Between 1 year after enrollment and 5 years after last patient in</time_frame>
    <description>Secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KCCQ-12</measure>
    <time_frame>Between 1 year after enrollment and 5 years after last patient in</time_frame>
    <description>Secondary endpoint</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">400</enrollment>
  <condition>SARS-CoV-2 Positive Patients</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>Patients with positive test for SARS-CoV-2 by PCR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients with negative SARS-CoV-2 antibody test</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      In the Control group a SARS-CoV-2 antibody test will be performed.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The SARS-CoV-2 positive patients in the Konstanz district are invited to participate in the&#xD;
        study by information letter. The addressing and sending of the study documents will take&#xD;
        place via the Health Department of the district of Konstanz. The study team only gets&#xD;
        knowledge of those positively tested patients who responded to the cover letter and declare&#xD;
        their informed consent to the study.&#xD;
&#xD;
        Probands for the control group will be contacted and invited to the study by announcements&#xD;
        in local newspapers and flyers in our hospital. Only those probands are included to the&#xD;
        study, who can be matched to one participant of the SARS-CoV-2 positive group by age,&#xD;
        gender and cardiovascular risk factors such as smoking, diabetes mellitus and arterial&#xD;
        hypertension.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A Inclusion Criteria of SARS-CoV-2 positive patients:&#xD;
&#xD;
        Patient must meet all of the following criteria.&#xD;
&#xD;
          1. Positive test for SARS-CoV-2 by PCR&#xD;
&#xD;
          2. Signed informed consent and privacy policy&#xD;
&#xD;
        B Inclusion Criteria of the control Group:&#xD;
&#xD;
        Volunteer must meet all of the following criteria.&#xD;
&#xD;
          1. No contact to SARS-CoV-2 positive patients&#xD;
&#xD;
          2. negative SARS-CoV-2 antibody test&#xD;
&#xD;
          3. Signed informed consent and privacy policy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patient/Volunteer will be excluded if any of the following conditions apply:&#xD;
&#xD;
          1. Patient/Volunteer age &lt; 18 years&#xD;
&#xD;
          2. Patient/Volunteer who are unable to read the information and understand the nature of&#xD;
             the study&#xD;
&#xD;
          3. Patient/Volunteer participate in any other clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Kollum, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hegau-Bodensee-Klinikum Singen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hegau-Bodensee-Klinikum Singen</name>
      <address>
        <city>Singen</city>
        <state>Baden-WÃ¼rttemberg</state>
        <zip>78224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hegau-Bodensee-Klinikum Singen</investigator_affiliation>
    <investigator_full_name>PD Dr. med. Marc Kollum</investigator_full_name>
    <investigator_title>Head of Cardiology and Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>COVID-19 Virus disease</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Hospitalization</keyword>
  <keyword>Quality of life</keyword>
  <keyword>EQ-5D-5L</keyword>
  <keyword>Cardiomyopathy, Kansas City (KCCQ-12)</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

